Project Description

Kidney Int. 2022 Apr;101(4):668-670. doi: 10.1016/j.kint.2021.12.032.

The ins and outs of ferric citrate.

Commentary: Enteral ferric citrate absorption is dependent on the iron transport protein ferroportin

Haase VH

Ferric citrate is used clinically for the treatment of hyperphosphatemia in patients with chronic kidney disease and is approved as an oral iron replacement product for patients with iron-deficiency anemia. In this issue of Kidney International, Hanudel and colleagues take advantage of genetic models with and without chronic kidney injury to demonstrate that the enteric absorption of iron delivered by ferric citrate is dependent on ferroportin expression and does not involve paracellular iron transport.

The ins and outs of ferric citrate

(click on image to view commentary)

link to paper by Hanudel and colleagues in Kidney International, April 2022